𝔖 Bobbio Scriptorium

✦ LIBER ✦

The “Dual-Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial

✍ Scribed by Cohen, Marc; Iyer, Deepa

Book ID: 127154992
Publisher: Hindawi Limited
Year: 2014
Tongue: English
Weight: 630 KB
Volume: 32
Category: Article
ISSN: 1755-5914
DOI: 10.1111/1755-5922.12083

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RIVAROXABAN IN THE SETTING OF CONTINUED

RIVAROXABAN IN THE SETTING OF CONTINUED DUAL ANTIPLATELET THERAPY: FINDINGS FROM THE ATLAS ACS 2-TIMI 51 TRIAL

✍ Mega, Jessica L.; Braunwald, Eugene; Murphy, Sabina; Plotnikov, Alexei; Cook-Bru 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 223 KB

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB